Hemosiderosis

Summary

Hemosiderosis (MONDO:0001436) is a disease and 10 clinical trials. Top therapeutic interventions include deferasirox, deferoxamine, and deferiprone. A subtype of iron metabolism disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemosiderosis
Mondo ID	MONDO:0001436
MeSH	D006486
DOID	DOID:12119
NCIT	C82892
SNOMED CT	39011001
UMLS	C0019114
MedGen	42409
Is cancer (heuristic)	no

Disease family

This is a subtype of iron metabolism disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › mineral metabolism disease › iron metabolism disease › hemosiderosis

Related subtypes (1): neurodegeneration with brain iron accumulation

Subtypes (3): ocular siderosis, hereditary hemochromatosis, pulmonary hemosiderosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Deferasirox	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE4	2
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00105495	PHASE4	COMPLETED	Efficacy Study in Removing Excess Iron From the Heart
NCT00171301	PHASE4	COMPLETED	Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
NCT00171171	PHASE3	COMPLETED	A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
NCT00469560	PHASE3	COMPLETED	Safety, Tolerability, and Efficacy of Deferasirox in MDS
NCT00303329	PHASE2	COMPLETED	Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT07028112	Not specified	RECRUITING	Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.
NCT01516853	Not specified	COMPLETED	Non-invasive Quantification of Liver Iron With MRI
NCT01623895	Not specified	COMPLETED	Pharmacogenetic Study in Patients Received Iron Chelating Agent
NCT02025543	Not specified	COMPLETED	Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
NCT04284371	Not specified	TERMINATED	The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEFERASIROX	4	4
DEFEROXAMINE	4	3
DEFERIPRONE	4	1